| 重组人尿激酶原静脉溶栓治疗STEMI的疗效和安全性研究 |
| |
| 引用本文： | 高宏波,郭欣,王永进,卫娇娜,丁钰轩,杜亚坤,白晓君,赵宽,黄新亮. 重组人尿激酶原静脉溶栓治疗STEMI的疗效和安全性研究[J]. 心脏杂志, 2022, 34(3): 289-292. DOI: 10.12125/j.chj.202107021 |
| |
| 作者姓名： | 高宏波 郭欣 王永进 卫娇娜 丁钰轩 杜亚坤 白晓君 赵宽 黄新亮 |
| |
| 作者单位： | 1.汉中市人民医院心内科, 陕西 汉中 723000 |
| |
| 摘 要： | ![]()
目的 观察重组人尿激酶原(rhPro-UK) 经静脉溶栓治疗急性ST段抬高型心肌梗死(STEMI)的临床疗效和安全性。 方法 选择汉中市人民医院静脉溶栓治疗的STEMI患者，根据患者溶栓药物不同分为重组人尿激酶原组(n=206)和尿激酶组(n=92)，收集两组患者的基线资料和冠状动脉造影资料，比较两组患者临床冠脉再通率、冠脉造影TIMI≥2级开通率、主要出血事件和其他并发症发生率。 结果 与尿激酶组患者比较，重组人尿激酶原组临床再通率[164(79.62 %) vs. 52(63.04 %), P<0.01]和TIMI≥2级开通率[149(82.78 %) vs. 50(65.79 %), P<0.01]显著提高，且主要出血事件[15(7.8 %) vs. 14(15.22 %), P<0.05]和并发症发生率[5(2.3 %) vs. 8(8.70%), P<0.05]显著降低。 结论 重组人尿激酶原静脉溶栓治疗 STEMI 患者血管再通率优于尿激酶，且出血事件及其他并发症发生率低。
|
| 关 键 词： | 重组人尿激酶原 静脉溶栓 急性 ST 段抬高型心肌梗死 |
| 收稿时间： | 2021-07-10 |
Efficacy and safety of thrombolytic therapy using recombinant prourokinase in patients with acute myocardial infarction with ST-segment elevation |
| |
| Affiliation: | 1.Department of Cardiology, Hanzhong People’s Hospital, Hanzhong 723000, Shaanxi, China2.Department of Cardiology, Hospital of Unit 96605, Tonghua 134001, Jilin, China3.Department of Cardiology, First Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China4.Department of Cardiology, Hanzhong 3201 Hospital, Hanzhong 723000, Shaanxi, China |
| |
| Abstract: | ![]()
AIM To observe the clinical efficacy and safety of thrombolytic therapy using recombinant prourokinase (rhPro-UK) in patients with acute myocardial infarction with ST-segment elvation (STEMI). METHODS STEMI patients with thrombolysis were selected and were divided into recombinant prourokinase group (n=206) and urokinase group (n=92). Baseline data of the two groups were collected, and clinical coronary recanalization rate, coronary angiography TIMI≥2 opening rate, major bleeding events and complication rate were compared between the two groups. RESULTS Compared with those in urokinase group, the clinical recanalization rate [164 (79.62%) vs. 52 (63.04%), P<0.01] and the opening rate of TIM≥2 [149 (82.78%) vs. 50 (65.79%), P<0.01] were significantly improved in recombinant prourokinase group, while the major bleeding events [15 (7.8%) vs. 14(15.22%), P<0.05] and the complication rate [5 (2.3%) vs. 8 (8.70%), P<0.05] were significant reduced. CONCLUSION Recombinant prourokinase has a higher rate of thrombolytic vascular recanalization and a lower incidence of bleeding events and complications. |
| |
| Keywords: | |
|
| 点击此处可从《心脏杂志》浏览原始摘要信息 |
|
点击此处可从《心脏杂志》下载免费的PDF全文 |
|
